Clinical Observation Of Shenqi Injection Combined With Docetaxel/cisplatin(DP)chemotherapy And Intrapleural Injection Of Cisplation On Non-Small Cell Lung Cancer-mediated Maligant Pleural Effusion

Objective To observe the clinical efficacy of Shenqi injection combined DP(docetaxel /cisplatin) chemotherapy for non-small cell lung cancer by comparing the clinical efficacy,chemotherapy toxicity and the differences impact for quality of life,and try to find the scientific and theoretical basis that useing shenqi injection treament non-small cell lung cance.Method Select a total number of 42 non-small cell lung cancer patients from October 2013 to March 2015 in Respiratory period of the first Hospital of Lanzhou University,who had pleural effusion,all of them were randomly dicided into treatment group and control group,21 cases in each group. Control group was treated single chemotherapy; Treatment group were combined with intravenous infusion of shenqifuzheng injection before 3 days of the treated with chemotherapy.Evaluated the the clinical efficacy of in the treatment of pleural effusion, gastrointestnal rection and the patients’ quality of life.Results Compared with control group, the situation of pleural effusion which is controled was significantly different(85.7%,47.62%,Respectively),treatment group had a better effective than control group(P<0.05),KPS had a higher sore(P<0.05),the incidence of gastrointestinal reactions and adverse reactions was reduced(P<0.05).Conclusion Shenqifuzheng injection combined with docetaxel / cisplatin(DP)chemotherapy and intrapleural injection of cisplatin in the patients of non-small cell lung cancer(NSCLC) can effectively reduce the production of pleural e ffusion, improve the clinical symptoms and quality of life and reduce the toxicity of chemotherapy.